Sign In
Buy ARCT
$5.76
-0.160 (-2.70%)
At Close: Jul 31, 2026
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
08:00am, Thursday, 20'th Jun 2024
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the deve
Arcturus: A Hidden Gem In The Biotech Sector
02:42am, Saturday, 08'th Jun 2024
Arcturus is a top pick in the biotech sector with a strong stock market performance. The company generates revenue from research and development partnerships, which helps conserve cash. The launch of
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
10:30am, Friday, 07'th Jun 2024
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the deve
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
06:30am, Tuesday, 28'th May 2024
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company
KING OF PRUSSIA, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Commun
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
04:01pm, Wednesday, 15'th May 2024
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the deve
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
11:05am, Wednesday, 01'st May 2024
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
04:01pm, Thursday, 25'th Apr 2024
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the deve
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript
06:32pm, Thursday, 07'th Mar 2024
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public R
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
06:11pm, Thursday, 07'th Mar 2024
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $1.69. This compares to earnings of $4.33 per share a year ago.
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
04:01pm, Thursday, 07'th Mar 2024
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the deve
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
02:26pm, Monday, 04'th Mar 2024
Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
03:20pm, Monday, 26'th Feb 2024
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
09:00am, Monday, 26'th Feb 2024
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company
